Edlund, Per, et al. “Dose-Tailoring of FEC Adjuvant Chemotherapy Based on Leukopenia Is Feasible and Well Tolerated. Toxicity and Dose Intensity in the Scandinavian Breast Group Phase 3 Adjuvant Trial SBG 2000-1”. Acta Oncologica, vol. 50, no. 3, Apr. 2011, pp. 329-37, doi:10.3109/0284186X.2011.554435.